vs
豪洛捷（HOLX）与RUSH ENTERPRISES INC \TX\（RUSHA）财务数据对比。点击上方公司名可切换其他公司
RUSH ENTERPRISES INC \TX\的季度营收约是豪洛捷的1.6倍（$1.7B vs $1.0B），豪洛捷净利率更高（17.1% vs 3.7%，领先13.4%），豪洛捷同比增速更快（2.5% vs -9.0%），RUSH ENTERPRISES INC \TX\自由现金流更多（$411.6M vs $215.2M），过去两年豪洛捷的营收复合增速更高（1.5% vs -6.8%）
豪洛捷是一家总部位于美国的医疗科技企业，核心业务聚焦女性健康领域，旗下产品涵盖诊断、外科手术及医学影像类专业医疗设备，为全球各地的医疗场景提供优质技术与产品支持。
Rush Enterprises是总部位于美国得克萨斯州新布朗费尔斯的商用车经销商，核心业务是通过旗下Rush Truck Centers销售全新及二手卡车。2019年该公司在全美20个州运营超200家卡车中心，在加拿大设有14个网点，2020年入选财富500强榜单。
HOLX vs RUSHA — 直观对比
营收规模更大
RUSHA
是对方的1.6倍
$1.0B
营收增速更快
HOLX
高出11.5%
-9.0%
净利率更高
HOLX
高出13.4%
3.7%
自由现金流更多
RUSHA
多$196.4M
$215.2M
两年增速更快
HOLX
近两年复合增速
-6.8%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $1.7B |
| 净利润 | $179.1M | $61.7M |
| 毛利率 | 56.0% | 20.4% |
| 营业利润率 | 22.6% | 4.9% |
| 净利率 | 17.1% | 3.7% |
| 营收同比 | 2.5% | -9.0% |
| 净利润同比 | -10.9% | 1.8% |
| 每股收益（稀释后） | $0.79 | $0.77 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HOLXRUSHA
| Q1 26 | — | $1.7B | ||
| Q4 25 | $1.0B | $1.7B | ||
| Q3 25 | $1.0B | $1.8B | ||
| Q2 25 | $1.0B | $1.8B | ||
| Q1 25 | $1.0B | $1.8B | ||
| Q4 24 | $1.0B | $1.9B | ||
| Q3 24 | $988.0M | $1.8B | ||
| Q2 24 | $1.0B | $1.9B |
净利润HOLXRUSHA
| Q1 26 | — | $61.7M | ||
| Q4 25 | $179.1M | $64.3M | ||
| Q3 25 | $187.2M | $66.7M | ||
| Q2 25 | $194.9M | $72.4M | ||
| Q1 25 | $-17.4M | $60.3M | ||
| Q4 24 | $201.0M | $74.8M | ||
| Q3 24 | $178.6M | $79.1M | ||
| Q2 24 | $194.5M | $78.7M |
毛利率HOLXRUSHA
| Q1 26 | — | 20.4% | ||
| Q4 25 | 56.0% | 20.8% | ||
| Q3 25 | 55.6% | 21.0% | ||
| Q2 25 | 56.3% | 20.7% | ||
| Q1 25 | 37.5% | 20.3% | ||
| Q4 24 | 56.8% | 19.3% | ||
| Q3 24 | 56.4% | 21.0% | ||
| Q2 24 | 55.4% | 20.2% |
营业利润率HOLXRUSHA
| Q1 26 | — | 4.9% | ||
| Q4 25 | 22.6% | 5.5% | ||
| Q3 25 | 22.6% | 5.6% | ||
| Q2 25 | 24.9% | 6.0% | ||
| Q1 25 | -0.7% | 5.2% | ||
| Q4 24 | 22.5% | 5.8% | ||
| Q3 24 | 23.3% | 6.7% | ||
| Q2 24 | 24.1% | 6.4% |
净利率HOLXRUSHA
| Q1 26 | — | 3.7% | ||
| Q4 25 | 17.1% | 3.8% | ||
| Q3 25 | 17.8% | 3.7% | ||
| Q2 25 | 19.0% | 3.9% | ||
| Q1 25 | -1.7% | 3.4% | ||
| Q4 24 | 19.7% | 3.9% | ||
| Q3 24 | 18.1% | 4.4% | ||
| Q2 24 | 19.2% | 4.1% |
每股收益（稀释后）HOLXRUSHA
| Q1 26 | — | $0.77 | ||
| Q4 25 | $0.79 | $0.81 | ||
| Q3 25 | $0.84 | $0.83 | ||
| Q2 25 | $0.86 | $0.90 | ||
| Q1 25 | $-0.08 | $0.73 | ||
| Q4 24 | $0.87 | $-95.13 | ||
| Q3 24 | $0.75 | $0.97 | ||
| Q2 24 | $0.82 | $97.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.4B | — |
| 总债务越低越好 | $2.5B | $277.8M |
| 股东权益账面价值 | $5.2B | $2.3B |
| 总资产 | $9.2B | $4.5B |
| 负债/权益比越低杠杆越低 | 0.48× | 0.12× |
8季度趋势，按日历期对齐
现金及短期投资HOLXRUSHA
| Q1 26 | — | — | ||
| Q4 25 | $2.4B | $212.6M | ||
| Q3 25 | $2.2B | $242.0M | ||
| Q2 25 | $1.9B | $211.1M | ||
| Q1 25 | $1.6B | $228.7M | ||
| Q4 24 | $2.0B | $228.1M | ||
| Q3 24 | $2.3B | $185.1M | ||
| Q2 24 | $2.4B | $167.3M |
总债务HOLXRUSHA
| Q1 26 | — | $277.8M | ||
| Q4 25 | $2.5B | $274.8M | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.5B | $408.4M | ||
| Q3 24 | $2.5B | — | ||
| Q2 24 | $2.5B | — |
股东权益HOLXRUSHA
| Q1 26 | — | $2.3B | ||
| Q4 25 | $5.2B | $2.2B | ||
| Q3 25 | $5.0B | $2.2B | ||
| Q2 25 | $4.8B | $2.2B | ||
| Q1 25 | $4.6B | $2.2B | ||
| Q4 24 | $4.8B | $2.1B | ||
| Q3 24 | $5.1B | $2.1B | ||
| Q2 24 | $5.0B | $2.0B |
总资产HOLXRUSHA
| Q1 26 | — | $4.5B | ||
| Q4 25 | $9.2B | $4.4B | ||
| Q3 25 | $9.0B | $4.6B | ||
| Q2 25 | $8.8B | $4.7B | ||
| Q1 25 | $8.5B | $4.7B | ||
| Q4 24 | $8.7B | $4.6B | ||
| Q3 24 | $9.2B | $4.6B | ||
| Q2 24 | $8.9B | $4.5B |
负债/权益比HOLXRUSHA
| Q1 26 | — | 0.12× | ||
| Q4 25 | 0.48× | 0.12× | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | 0.19× | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $229.9M | — |
| 自由现金流经营现金流 - 资本支出 | $215.2M | $411.6M |
| 自由现金流率自由现金流/营收 | 20.5% | 24.4% |
| 资本支出强度资本支出/营收 | 1.4% | 2.0% |
| 现金转化率经营现金流/净利润 | 1.28× | — |
| 过去12个月自由现金流最近4个季度 | $1.0B | $828.4M |
8季度趋势，按日历期对齐
经营现金流HOLXRUSHA
| Q1 26 | — | — | ||
| Q4 25 | $229.9M | $112.9M | ||
| Q3 25 | $355.1M | $367.8M | ||
| Q2 25 | $343.3M | $227.6M | ||
| Q1 25 | $169.4M | $153.5M | ||
| Q4 24 | $189.3M | $392.3M | ||
| Q3 24 | $367.0M | $111.7M | ||
| Q2 24 | $405.8M | $270.6M |
自由现金流HOLXRUSHA
| Q1 26 | — | $411.6M | ||
| Q4 25 | $215.2M | $31.9M | ||
| Q3 25 | $341.4M | $271.2M | ||
| Q2 25 | $330.5M | $113.8M | ||
| Q1 25 | $153.9M | $45.1M | ||
| Q4 24 | $172.5M | $263.5M | ||
| Q3 24 | $350.6M | $-20.0M | ||
| Q2 24 | $385.3M | $177.2M |
自由现金流率HOLXRUSHA
| Q1 26 | — | 24.4% | ||
| Q4 25 | 20.5% | 1.9% | ||
| Q3 25 | 32.5% | 15.2% | ||
| Q2 25 | 32.3% | 6.2% | ||
| Q1 25 | 15.3% | 2.6% | ||
| Q4 24 | 16.9% | 13.7% | ||
| Q3 24 | 35.5% | -1.1% | ||
| Q2 24 | 38.1% | 9.1% |
资本支出强度HOLXRUSHA
| Q1 26 | — | 2.0% | ||
| Q4 25 | 1.4% | 4.8% | ||
| Q3 25 | 1.3% | 5.4% | ||
| Q2 25 | 1.3% | 6.2% | ||
| Q1 25 | 1.5% | 6.2% | ||
| Q4 24 | 1.6% | 6.7% | ||
| Q3 24 | 1.7% | 7.3% | ||
| Q2 24 | 2.0% | 4.8% |
现金转化率HOLXRUSHA
| Q1 26 | — | — | ||
| Q4 25 | 1.28× | 1.75× | ||
| Q3 25 | 1.90× | 5.51× | ||
| Q2 25 | 1.76× | 3.14× | ||
| Q1 25 | — | 2.55× | ||
| Q4 24 | 0.94× | 5.25× | ||
| Q3 24 | 2.05× | 1.41× | ||
| Q2 24 | 2.09× | 3.44× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
RUSHA
| New and used commercial vehicle sales | $955.1M | 57% |
| Aftermarket products and services sales | $627.2M | 37% |
| Lease and rental sales | $92.3M | 5% |
| Finance and insurance | $5.6M | 0% |
